Colorectal cancer cell growth

Colorectal cancer cell growth is a complex pathological process characterized by the rapid and unregulated proliferation of epithelial cells in the colon or rectum (National Cancer Institute, 2023). This process is primarily driven by sequential genetic alterations, including mutations in the APC, KRAS, and TP53 genes, which disrupt normal cellular homeostasis and promote survival (Vogelstein et al., 2013). Key signaling cascades involved in promoting this growth include the Wnt/beta-catenin pathway, the epidermal growth factor receptor (EGFR) pathway, and the vascular endothelial growth factor (VEGF) pathway (Punt et al., 2017). While many drugs are designed to inhibit this expansion, the term itself refers to a phenotypic outcome or a disease manifestation rather than a specific protein, receptor, or enzyme that can be directly drugged. Consequently, in a drug discovery context, this is classified as a biological process or physiological state rather than a discrete therapeutic target. Targeting this growth involves the use of diverse therapeutic agents, such as monoclonal antibodies like cetuximab or small molecule inhibitors, that target the underlying molecular drivers of the malignancy (Siena et al., 2009). Overall, while it is the primary focus of oncological intervention, it does not represent a singular molecular entity.

Other names

CRC cell proliferationColorectal tumor growthColorectal carcinoma proliferationMalignant growth of the colon

Inhibition of DNA synthesis, blockade of growth factor signaling (e.g., EGFR), or inhibition of angiogenesis (VEGF) to arrest the cell cycle and induce apoptosis.